Talazoparib Tosylate

New evidence for established standard-of-care therapies, with updates for LORBRENA ® in ALK-positive metastatic non ‑ small cell lung cancer and a BRAFTOVI ® regimen in a type of BRAF-mutant colorectal cancer NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 – June 2, 2026, in Chicago. Data from more than 40 company-sponsored, investigator-sponsored and collaborative research abstracts, including three late-breaking sessions and eight oral and rapid oral presentations, will be shared. These data highlight Pfizer’s leadership in establishing potential new standards of care across multiple cancer types and its next-generation pipeline of novel targets and combination strategies designed to extend impact into broader patient populations and earlier lines of therapy. “For people living with cancer and their families, every moment matters. We are moving with urgency to drive advances that have the potential to change standards of care – and striving to bring new, innovative options to patients in earlier lines of therapy,” said Jeff Legos, Chief Oncology Officer, Pfizer. “Our progress is evident in the data presented at ASCO this year, which span our portfolio of established therapies, as well as next-generation, early-stage clinical research from one of the industry’s largest oncology R&D programs. Together, these results reinforce our ability to advance breakthroughs that may redefine clinical practice and change the lives of people with cancer.” Key highlights of Pfizer’s presence at ASCO include: Sharing new evidence for standard-of-care therapies in certain types of biomarker-driven colorectal and lung cancers Seven-year update from the pivotal Phase 3 CROWN study further supports LORBRENA ® (lorlatinib) as a guideline-recommended first-line treatment for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Late-breaking presentation of progression-free survival (PFS) and overall survival (OS) data from Cohort 3 of the BREAKWATER* trial evaluating BRAFTOVI ® (encorafenib) in combination with cetuximab and FOLFIRI (fluorouracil, leucovorin and irinotecan) as a first-line regimen for patients with BRAF V600E- mutant metastatic colorectal cancer (mCRC). These pivotal data further establish the benefit of this BRAFTOVI regimen following the U.S. Food and Drug Administration (FDA) full approval and the topline results announcement for objective response rate (ORR) from this Cohort earlier this year. Showcasing data on potential benefit of treatments in earlier lines of therapy for prostate and breast cancers Late-breaking presentation from the Phase 3 TALAPRO-3 study will highlight clinically meaningful radiographic progression-free survival (rPFS) benefit for TALZENNA ® (talazoparib) plus XTANDI ® ** (enzalutamide) in metastatic castration‑sensitive prostate cancer (mCSPC) patients with homologous recombination repair gene alterations, with effects consistent across subgroups and a strong OS trend. These data follow the announcement of topline results in March 2026 and support the potential of TALZENNA plus XTANDI to deliver benefit earlier in the disease course. Additional efficacy and safety outcomes by stratified subgroups from the Phase 3 HER2CLIMB-05 study investigating TUKYSA ® (tucatinib) in combination with trastuzumab and pertuzumab as first-line maintenance therapy for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). These results support TUKYSA’s potential use as part of a chemotherapy-free, first-line maintenance strategy for HER2+ MBC. Advancing next-generation pipeline of novel mechanisms and differentiated combinations across solid tumors Updated Phase 2 data for PF‑08634404 (PF’4404), a novel bispecific antibody targeting PD-1 and VEGF, as monotherapy in first-line PD-L1-expressing NSCLC. PF’4404 is being developed as a potential backbone therapy across tumor types, including an ongoing Symbiotic-Lung-01 Phase 3 study in combination with chemotherapy in first-line NSCLC regardless of PD-L1 expression and an ongoing Symbiotic-GI-03 Phase 3 study in first-line mCRC. Updated results from a Phase 1 study of sigvotatug vedotin (SV), a novel integrin β6 (IB6)–directed ADC, in combination with pembrolizumab in NSCLC. These data support the ongoing SigVie-003 Phase 3 study of SV in combination with pembrolizumab in first-line NSCLC. An additional ongoing Phase 3 study, SigVie-002, is evaluating SV monotherapy in patients previously treated for advanced NSCLC. The first results from a Phase 2 study of neoadjuvant atirmociclib, a highly selective CDK4 inhibitor, in combination with letrozole versus letrozole alone in people with hormone receptor-positive (HR+), HER2- breast cancer. Atirmociclib is being developed as a potential first-in-class, next-generation cell cycle inhibitor backbone for HR+, HER2- breast cancer in the early adjuvant and first-line metastatic setting. Findings from a Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544 (polfurmetinib), plus a next-generation BRAF inhibitor, PF-07799933 (claturafenib), in advanced BRAF-mutant melanoma. Information on significant Pfizer and partner-sponsored abstracts, including date and time of presentation, follows in the chart below. A complete list of Pfizer and partner-sponsored abstracts and presentations is available here. LUNG CANCER Oral Presentation (Abstract 8502) May 29, 2026 1:00 PM-4:00 PM CDT Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study Mok et al Rapid Oral Presentation (Abstract 8514) May 30, 2026 1:15 PM-2:45 PM CDT Updated results from a phase 2 trial of SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, as monotherapy in patients with advanced non-small cell lung cancer (NSCLC) Wu et al Poster Presentation (Abstract 8522) May 31, 2026 9:00 AM-12:00 PM CDT Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody-drug conjugate (ADC), plus pembrolizumab: updated results from phase 1 study (SGNB6A-001) Jaime et al Poster Presentation (Abstract 8609) May 31, 2026 9:00 AM-12:00 PM CDT Reduction in circulating tumor DNA (ctDNA) significantly correlates with radiographic response and tumor PD-L1 expression in a phase 1 study of PDL1V (PF-08046054) in patients with non-small cell lung cancer (NSCLC) Saleh et al COLORECTAL CANCER Oral Presentation (Abstract LBA3503) May 31, 2026 8:00 AM-11:00 AM CDT BREAKWATER: Progression-free survival analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC) [LBA] Kopetz et al BREAST CANCER Oral Presentation (Abstract 1005) June 2, 2026 9:45 AM-12:45 PM CDT Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer (MBC) by stratified randomized subgroups Hamilton et al Rapid Oral Presentation (Abstract LBA1018) May 31, 2026 11:30 AM-1:00 PM CDT Palbociclib plus Tamoxifen ± goserelin in women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer (BC): PATHWAY, an Asian international double-blind randomized phase 3 trial: Final Overall Survival (OS) analysis [LBA] Lu et al Poster Presentation (Abstract 518) June 1, 2026 1:30 PM-4:30 PM CDT Neoadjuvant atirmociclib plus letrozole versus letrozole alone in women with HR+/HER2− breast cancer: results from FOURLIGHT-2, a randomized phase 2 window of opportunity study Goel et al Poster Presentation (Abstract 1042) June 1, 2026 1:30 PM-4:30 PM CDT Tucatinib (TUC) combined with trastuzumab and pertuzumab (HP) as first-line (1L) maintenance therapy for HER2+ metastatic breast cancer (MBC): an in-depth safety analysis of HER2CLIMB-05 Dieras et al Poster Presentation (Abstract 1068) June 1, 2026 1:30 PM-4:30 PM CDT Long-term safety and adverse event (AE) management in patients with ER+/HER2− metastatic breast cancer (mBC) receiving prifestrastat, a first-in-class KAT6 inhibitor, in combination with fulvestrant Layman et al BLADDER/GENITOURINARY CANCERS Oral Presentation (Abstract LBA5007) May 30, 2026 3:00 PM-6:00 PM CDT TALAPRO-3: Talazoparib (TALA) + enzalutamide (ENZA) compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations [LBA] Agarwal et al Oral Presentation (Abstract 4507) May 29, 2026 2:45 PM-5:45 PM CDT Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study Powles et al Oral Presentation (Abstract 4510) May 30, 2026 8:00 AM-9:30 AM CDT Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: phase 3 KEYNOTE-905 study [MSD led] O’Donnell et al Oral Presentation (Abstract 5006) May 30, 2026 3:00 PM-6:00 PM CDT Final results from ZZFIRST: a randomized phase 2 trial of enzalutamide (EZ) and talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC) Mateo et al Poster Presentation (Abstract 4613) May 31, 2026 9:00 AM-12:00 PM CDT Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants with cisplatin-ineligible muscle-invasive bladder cancer (MIBC): An analysis of clinically relevant subgroups in KEYNOTE-905 [MSD led] Adra et al Poster Presentation (Abstract 5043) May 31, 2026 9:00 AM-12:00 PM CDT Impact of baseline demographics on therapy management in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib (TALA) + enzalutamide (ENZA) in the TALAPRO-2 study: extended follow-up De Giorgi et al MELANOMA Rapid Oral Presentation (Abstract 9512) May 30, 2026 4:30 PM-6:00 PM CDT Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544, plus next-generation BRAF dimer inhibitor, PF-07799933, in advanced BRAF-mutant melanoma Chen et al MULTIPLE MYELOMA Oral Presentation (Abstract 7500) May 29, 2026 2:45 PM-5:45 PM CDT Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study Touzeau et al OTHER GYNECOLOGICAL CANCERS Poster Presentation (Abstract 5627) June 1, 2026 9:00 AM-12:00 PM CDT A phase 2 study evaluating SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, + chemotherapy (chemo) in patients (pts) with first-line (1L) advanced/recurrent endometrial cancer (EC) Zhou et al Pfizer is continuing its commitment to help non-scientists understand the latest findings with the development of abstract plain language summaries (APLS) for company-sponsored research being presented at ASCO, which are written in non-technical language. Those interested in learning more can visit www.Pfizer.com/apls to access the summaries. *The BREAKWATER trial was conducted with support from ONO Pharmaceutical, Merck KGaA, Darmstadt, Germany and Eli Lilly and Company. Pierre Fabre Laboratories also has exclusive rights to commercialize the product in all other countries, including Europe and Asia (excluding Japan and South Korea). **XTANDI® is jointly developed and commercialized by Pfizer and Astellas in the United States. Prescribing Information for Pfizer Medicines Please see full Prescribing Information for LORBRENA® (lorlatinib). Please see full Prescribing Information for BRAFTOVI® (encorafenib). Please see full Prescribing Information for TALZENNA® (talazoparib). Please see full Prescribing Information for XTANDI® (enzalutamide). Please see full Prescribing Information for TUKYSA® (tucatinib). About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including immune-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematologic malignancies, and lung cancers. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on X at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. Disclosure Notice The information contained in this release is as of April 21, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer Oncology and Pfizer’s oncology portfolio of marketed and investigational therapies, including their potential benefits; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data; the development or commercial potential of our product pipeline, in-line products, product candidates and additional indications or combinations, including expected clinical trial protocols, the potential and timing for the initiation and progress of clinical trials and data read-outs from trials; the timing and potential for the submission of applications for and receipt of regulatory approvals; the timing and potential for product launches and commercialization; expected breakthrough, best- or first-in-class or blockbuster status or expected market entry of our medicines; potential patients reached; the regulatory landscape; the competitive landscape; and other statements about our business, operations and financial results that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risk and uncertainties include, among other things, uncertainties regarding the commercial success of Pfizer’s oncology portfolio; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim and preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications, biologics license applications and/or emergency use authorization applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s products or product candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

编辑推荐——论文精选 2026年第一期 Current  Cancer Drug Targets 肿瘤药物靶点研究的重要国际期刊 期刊简介 Aims & Scope Current Cancer Drug Targets 旨在全面涵盖癌症药物发现与开发领域的最新及重大进展，包括但不限于以下方向： 细胞与分子生物学 基因组学、蛋白质组学、代谢组学 药物化学、药理学、毒理学与生物化学 癌症相关分子药物靶点（如疾病特异性蛋白、受体、酶及基因） 本期刊内容涵盖癌症药物靶点的各类前沿主题，重点发表以下类型的文章： 原创研究型文章 通讯/评论/观点 综述/短篇综述 药物临床试验研究 特邀专题（由相关学科领域领军学者主编） 随着人类抗癌药物新靶点的发现、鉴定、表征与验证研究持续增长，本期刊已成为生物医学与制药科学领域从事药物研发的必读刊物，重点关注机制层面的深度探索。其范围涵盖以下方向的基础与转化研究： 癌症预防、诊断与治疗 癌症病因学、信号转导、生物标志物 化疗、激素治疗、基因治疗、免疫治疗、放疗及联合疗法 干细胞、肿瘤微环境、代谢研究 期刊基本信息 ISSN (纸质版): 1568-0096 ISSN (电子版): 1873-5576 影响因子 (IF)： 3.5 （五年IF： 2.9） Indexed in：SCIE, ESI, JCR, Chemical Abstracts Service/SciFinder, Scopus, MEDLINE/PubMed, CNKI Scholar, Google Scholar, Cambridge Scientific Abstracts(CSA)/ProQuest等 JCR分区情况： Q2（ONCOLOGY 106/326） *期刊指标数据来源于Journal Citation Reports™ © 2025 Clarivate 本期特别精选由编辑推荐的已经发表在 Current Cancer Drug Targets 上的文章。该期刊现在已经发表的大部分文章都支持文摘一键翻译成中文，可提升文摘阅读效率，可在文章下载页面体验。 更多内容请访问期刊主页 https://www.eurekaselect.com/journal/7  扫描二维码，可直达主页 为了方便阅读，精选的文章都以译文展示，如需阅读原文可访问文章后面的链接或者扫描二维码 欢迎阅读并分享以下编辑推荐的文章 精选文章一： Review Article 文章标题：PARP1抑制剂的临床应用与癌症治疗挑战   文章摘要 Abstract 在哺乳动物聚腺苷二磷酸核糖聚合酶家族中，PARP1是首个被鉴定且研究最为深入的成员，在DNA损伤修复中发挥关键作用，并已被证实是癌症治疗的有效靶点。本文不仅综述了PARP1在不同DNA损伤修复通路中的作用，还阐述了多种PARP抑制剂的作用机制——通过抑制多聚腺苷二磷酸核糖基化过程和PAR链生成，将PARP1捕获在受损DNA上，并通过抑制PARP1活性诱导转录-复制冲突。本文系统总结了六种获批PARP抑制剂（包括奥拉帕利、芦卡帕利、尼拉帕利、他拉唑帕利、氟唑帕利和帕米帕利）在单药治疗以及与化疗、放疗、免疫治疗联合治疗多种癌症中的最新临床应用进展。此外，本文还讨论了PARP抑制剂应用中可能面临的挑战及耐药机制。尽管存在这些挑战，新型PARP1抑制剂的进一步开发仍有望成为癌症治疗的重要策略。 关键词：PARP1、PARylation、PARP抑制剂、奥拉帕尼、癌症治疗、耐药性。 Volume 26, Issue 1, 2026 Published on: 06 January, 2025 Page: [1 - 35] DOI: 10.2174/0115680096327635241021115944 扫码即可查看原文 原文链接：https://www.eurekaselect.com/article/145423 精选文章二： Review  Article 文章标题：HDAC6：肿瘤进展与多重功能解析   文章摘要 Abstract 组蛋白去乙酰化酶6（HDAC6）是癌症研究中备受关注的治疗靶点，作为HDAC家族中唯一主要定位于细胞质的成员而独具特色。HDAC6拥有两个催化结构域和一个独特的泛素结合结构域，这使其与其他HDACs区别开来。除了组蛋白去乙酰化功能外，HDAC6还可靶向多种非组蛋白底物，如α-微管蛋白、皮层肌动蛋白、热休克蛋白90及热休克因子1。其功能涉及肿瘤进展的关键环节，包括侵袭、转移、血管生成、耐药性、干性维持以及降低肿瘤细胞免疫原性。鉴于这些功能，HDAC6抑制剂正成为治疗实体瘤和血液系统肿瘤的重要工具。近年来多项HDAC6抑制剂已进入临床试验阶段并取得良好结果。本综述涵盖了HDAC6的结构特征、生物学功能及其对肿瘤发展的影响，重点关注与进展相关的事件。此外，还详细讨论了选择性HDAC6抑制剂的临床前及临床试验进展。 关键词：HDAC6；实体瘤；治疗靶点；选择性抑制剂；临床试验；热休克因子1。 Volume 26, Issue 1, 2026 Published on: 07 January, 2025 Page: [47 - 63] DOI: 10.2174/0115680096332732241113053459 扫码即可查看原文 原文链接：https://www.eurekaselect.com/article/145514 精选文章三： Research Article 文章标题：新型卵巢癌铂类耐药相关基因标签的鉴定及患者源性类器官验证   文章摘要 Abstract 背景：铂类化疗耐药是导致卵巢癌（OC）患者死亡的主要原因之一。识别铂类耐药人群的敏感生物标志物是当前亟待解决的问题。本研究旨在开发基于铂类耐药基因的预测模型，用于评估OC患者对铂类药物的反应及生存结局。 方法：通过生物信息学分析构建铂类耐药相关基因模型，并进行内部验证以评估其预测效能。构建列线图进一步确认模型的预测能力。采用GSEA分析模型基因的潜在功能，运用ESTIMATE、CIBERSORT、TIMER和ssGSEA评估免疫微环境特征。同时分析体细胞突变与药物敏感性。最后，通过患者源性肿瘤类器官验证靶基因在药物敏感性中的作用。 结果：成功构建包含9个铂类耐药相关基因（SLC22A2、TAP1、PC、MCM3、GTF2H2、FXYD5、SUPT6H、IGKC和MATN2）的预测模型，内部验证显示模型具有良好的预测效能。GSEA分析揭示模型基因富集于Hedgehog信号通路。该基因标签与PD-1、PD-L1、CTLA4等免疫检查点抑制剂相关，可为OC患者的免疫治疗应用提供指导。达沙替尼、米哚妥林、二甲双胍、MK-2206和丝裂霉素C等药物可能对具有不同风险评分的OC患者产生差异化疗效。患者源性类器官实验显示，高风险评分患者对顺铂的耐药性显著高于低风险评分患者。 结论：本研究建立的铂类耐药相关基因标签（SLC22A2、TAP1、PC、MCM3、GTF2H2、FXYD5、SUPT6H、IGKC和MATN2）对OC患者的预后预测和治疗选择具有重要指导价值。 关键词：卵巢癌；铂类耐药；基因标签；药物敏感性；预后；TCGA；类器官。 Volume 26, Issue 1, 2026 Published on: 30 January, 2025 Page: [64 - 84] DOI: 10.2174/0115680096326784241009113454 扫码即可查看原文 原文链接：https://www.eurekaselect.com/article/146274 Current Cancer Drug Targets 是一份聚焦癌症治疗领域的国际学术期刊，致力于发表涵盖分子靶点发现、药物设计、临床前研究以及新型治疗策略等领域的高质量原创研究和综述。期刊内容紧跟肿瘤学前沿，涵盖信号通路、免疫治疗、耐药机制、转化医学等多个热点方向，为科研人员、临床医生和药物研发人员提供前沿的学术交流平台。 我们诚挚邀请肿瘤学、药理学及相关领域学者投稿您的最新研究成果，与全球学者分享您的最新研究成果。 本刊实行严格的双盲同行评审，确保学术质量，并提供高效的出版服务。 该期刊所有发表的开放获取（Open Access）文章会同步上线至Elsevier出版社的ScienceDirect平台。 期待您的投稿，共同推动癌症治疗领域的进步！ 扫描上方二维码，即刻将您的科研成果投稿到本刊 星辰大海，永不止步 Bentham Science Publishers作为国际领先的学术出版机构，深耕医学、药学、化学等相关领域三十余年，以传播科学发现为使命，搭建起全球医药学相关科研交流的桥梁。 我们的学科积淀： • 累计出版1000+医药学相关期刊与专著 • 200余位诺奖得主及院士级学者任职编委参与审稿，保障学术权威性 • 高被引论文数量年均增长15%，众多文章被WHO、FDA等机构引用 • 订阅模式丰富，让科研成果触达165个国家 • 坚持双盲评审流程，践行科研诚信，坚守学术道德底线，遵循COPE（出版伦理委员会）指南，对学术不端行为零容忍。 扫描下方二维码 关注我们，及时获取出版社最新资讯 🌐 联系我们官网：https://www.eurekaselect.com 邮箱：cassie@benthamscience.ae 期待您的留言互动，您的需求将指引我们未来服务的方向 ✨Welcome to Bentham Science Publishers 编辑：徐玥 校对：赵金平，何涛 审核：颜旭英